H uman mutations in PRKAG2, the gene encoding the ␥ 2 subunit of AMP-activated protein kinase (AMPK), cause cardiomyopathy characterized by ventricular hypertrophy, Wolff-Parkinson-White syndrome (WPW), and progressive conduction system disease. [1] [2] [3] [4] [5] AMPK, consisting of catalytic (␣) and regulatory (␥ and ␤) subunits, is activated in energy-deficiency states and plays a key role in regulation of cardiac metabolism and energy homeostasis. 1 In vitro analyses of the biochemical consequences of disease-causing missense mutations in a yeast gene homologue (Snf4) and in transfected COS cells indicated that defects in humans caused constitutive kinase activity. 5, 6 We have documented vacuolar changes and periodic acid-Schiff (PAS)-positive inclusions, suggesting accumulation of glycogen-related material, in the hearts of affected individuals. 5 Although they clearly distinguish this entity from classic hypertrophic cardiomyopathy caused by sarcomere protein gene mutation, 7 the exact role played by glycogen stores in disease pathogenesis remains unclear.
An intriguing and poorly understood aspect of this disorder is the conduction system disease associated with PRKAG2 mutations. Affected individuals typically demonstrate ECG patterns of ventricular preexcitation and other features associated with WPW. 2, 5, 8 WPW is generally thought to be caused by muscular tracts that connect atrium to ventricle outside the specialized conduction tissue such that electrical impulses traversing these tracts bypass the physiological atrioventricular node delay and produce ventricular preexcitation. In most patients with WPW, however, the anatomic substrate for ventricular preexcitation is undefined. Morphological studies of hearts from individuals with PRKAG2 mutations have not been performed, and whether these mutations cause bypass tracts is unknown.
We developed transgenic mice overexpressing the PRKAG2 N488I missense mutation to define the mechanisms by which this mutation causes cardiac disease; because human PRKAG2 mutations create a "gain of function," 5 a transgenic mouse overexpressing the mutant gene appeared to be a suitable model system. The transgenic mice expressed either wild-type or mutant (N488I) PRKAG2 cDNA under control of the cardiac-specific ␣-myosin heavy chain (␣-MHC) promoter 9 ( Figure 1A ). Transgenic mice carrying the mutant but not wild-type human PRKAG2 cDNA developed both cardiac hypertrophy and ventricular preexcitation. Our analyses of these mice define the anatomic basis for preexcitation in this human cardiomyopathy.
Methods

Transgenic Mice
The PRKAG2 coding region was amplified from human lymphocyte RNA by use of the One-Step reverse transcription-polymerase chain reaction (RT-PCR) kit (Qiagen) with primers 29F, 5Ј-GGGAGGGAAGGAGGGGACCGAACC-3Ј, and 1880R, 5Ј-GCAGCCAGTGTTCATGAGGCAAAAC-3Ј). An 1851-bp fragment was isolated and subcloned into pCR R IITOPO R vector (TOPO TA cloning kit, Invitrogen). The nucleotide sequences of 20 cloned inserts were determined to identify 1 insert that was identical to human PRKAG2 cDNA. A T3 A substitution was introduced at nucleotide residue 1553 to encode the Asn3 Ile missense mutation (at codon 488, designated N488I 5 ). Wild-type and mutant cDNA inserts were released by EcoRI digestion and blunt-end-ligated into the SalI site of pC126 expression vector. 9 Transgene DNA encoding the ␣-MHC promoter, PRKAG2 coding sequence, human growth hormone 3Ј-UTR, and a polyA signal ( Figure 1A ) were linearized with BamHI; size-fractionated; purified (QIAquick Gel Extraction Kit, Qiagen); and microinjected into fertilized FVB mouse oocytes.
Genotyping
Transgenic founders were identified by Southern blot analyses of tail DNA as described previously, 10 except that a 540-bp antisense biotinylated riboprobe (Strip-EZ RNA Kit, Ambion) corresponding to the 3Ј end of the cloned cDNA was used to identify the 1000-bp HindIII transgene-specific fragment. Offspring of founder mice were genotyped by PCR amplification of the transgene using primers F, 5Ј-GCCTGCTTTCATGAAGCAGAA-3Ј, and R, 5Ј-GCAGCCAG-TGTTCATGAGGCAAAAC-3Ј, and a control mouse genomic fragment using primers F, 5Ј-GAGAACTCGGCATGCCAGATTC-3Ј, and R, 5Ј-ACTCAGCAAGCCTTCCCATCTG-3Ј, in 1 reaction.
RNA Assessment
Northern blots were performed as described 10 using 2 g total cardiac RNA per gel lane and biotinylated riboprobes prepared as above. Semiquantitative RT-PCR using the above-mentioned PRKAG1 and PRKAG2 primers was performed as described. 11 Band intensities were quantified by densitometry using NIH Image software.
Protein Analyses
Protein extracts and Western blots were performed as described 6 using 10 to 20 g of protein lysate per lane. Antibodies specific for the AMPK ␥ 2 peptide (556 to 569 LTPAGAKQKETETE-COOH), ␣ 1 , ␣ 2 , and pan-␤ (Upstate Biotechnology) were diluted 1000-to 2000-fold. Horseradish peroxidase-conjugated secondary antibody was used for chemiluminescence detection. heart section containing right atrium (A), right ventricle (V), tricuspid valve (TV), and annulus fibrosis (arrow) using AMPK ␥ 2 subunit antibody.
Biochemical Assays
Glycogen content was determined by the amyloglucosidase digestion method 12 on cardiac tissue that was rapidly excised, instantly immersed in ice-cold PBS, blotted, and freeze-clamped. Glucose was determined with the glucose oxidase kit (Sigma). AMPK activity was assessed by its ability to phosphorylate a synthetic peptide. 13 AMPK complexes were immunoprecipitated from 200 g protein using ␣ 1 -or ␣ 2 -specific antibody and protein A/G Plus-Agarose beads (Santa Cruz Biotechnology). AMPK activity with or without 200 mol/L AMP was determined by the phosphorylation of a synthetic "SAMS" peptide (HMRSAMSGLHLVKRR).
Echocardiography and ECG
Echocardiography was performed in male mice with a SONOS-4500 Hewlett-Packard echocardiograph as described previously, 10 except that mice were anesthetized before hair removal. ECG recordings, electrophysiological studies, and continuous ECG recordings (Holter monitor) were performed as described previously. 14 
Histopathology
Mouse hearts were fixed and stained as described previously. 5, 10 Sections for immunohistochemistry were deparaffinized, incubated with AMP kinase ␥ 2 antibody and fluorescein-conjugated secondary antibody, and examined under a fluorescence microscope. For electron microscopy, 1-m sections fixed in glutaraldehyde were embedded in Epon 812 and stained with toluidine blue. Hearts were analyzed for accessory atrioventricular connections by serial analyses of 5-m sections taken every 20 m. 15, 16 The morphology of the native conduction system was analyzed in genetically engineered mice that express ␤-galactosidase under the endogenous MinK promoter. 17 ␤-Galactosidase was assayed in whole explanted hearts by use of an X-gal-based kit from Specialty Media (www.SpecialtyMedia.com). 
Data Analysis
Results
A full-length human PRKAG2 cDNA, which encodes a 569-amino-acid polypeptide 18 and is 95% similar to the mouse homologue, was amplified from lymphocyte RNA and used as a transgene (see Methods and Figure 1A) . A second transgene was created by mutating codon 488 from Asn3 Ile. Seven independent transgenic lines expressed robust amounts of wild-type PRKAG2 RNA (denoted TG wt ), and 8 independent lines expressed abundant N488I PRKAG2 RNA (denoted TG N488I ) levels. Heterozygous offspring from TG wt founder 4657 and TG N488I founder 4623 were used for further analyses because of comparable transgene RNA expression. Each transgenic mouse carried Ϸ20 copies of the transgene (data not shown) and expressed at least 20-fold more cardiac PRKAG2 RNA than nontransgenic mice ( Figure 1B) .
Transgene-encoded AMPK ␥ 2 protein was not detected in newborn transgenic mice, presumably because the ␣-MHC promoter does not become fully active until after neonatal life. 19 In young and adult transgenic mice, AMPK ␥ 2 protein was abundant in atrial and ventricular myocardium ( Figure 1 , C and D). AMPK ␥ 2 protein levels in TG N488I and TG wt hearts were Ϸ20-fold higher than endogenous ␥ 2 subunit protein levels in nontransgenic mice, but PRKAG2 overexpression did not affect the levels of endogenous PRKAG1 mRNA or the levels of other AMPK subunits ( Figure 1, B mild morphological changes despite significantly increased glycogen content. Cardiac weight and left ventricular wall thickness were increased compared with wild-type mouse hearts (Table) , but TG wt hearts had neither histopathological changes (Figure 2 ) nor cardiac dysfunction associated with glycogen storage. In contrast, TG N488I mice had strikingly abnormal cardiac morphology and histology. Cardiac mass and left ventricular wall thickness were markedly increased in TG N488I mice compared with nontransgenic controls or TG wt mice ( Figure 2 , A-C, and Table) . Histological analyses (Figure 2 , D-I) showed myocyte hypertrophy; PAS staining revealed abundant glycogen throughout the myocardium. Ventricular but not atrial myocytes contained vacuoles, which were similar to those observed in cardiac histopathology of humans bearing a PRKAG2 mutation. 5 Electron microscopy revealed that vacuoles contained pooled, non-membranebound glycogen, which displaced contractile elements and distorted the overall cell morphology ( Figure 2K ). Neither interstitial fibrosis nor lipid deposition was evident.
The cardiac function of TG N488I mice deteriorated over time. Echocardiograms of TG N488I mice showed cardiac hypertrophy with near-normal fractional shortening at 8 to 10 weeks, but by 20 weeks of age, contractile function was reduced and chamber dilation was evident (Table) . Cardiac hypertrophy was associated with a proportional increase in protein content (Table) and augmented ventricular expression of hypertrophy-related genes: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and ␣-skeletal actin ( Figure 3) . ANP, BNP, and ␣-skeletal actin RNA in TG wt hearts were 6-, 3-, and 4-fold greater than in nontransgenic hearts, respectively (3 to 4 mice per group; PϽ0.05), whereas these RNAs were 20-, 10-, and 8-fold greater in TG N488I than in nontransgenic hearts. ANP and BNP RNAs were expressed at a significantly higher level in TG N488I than in TG wt hearts (PϽ0.025).
Because human PRKAG2 missense mutations caused ventricular preexcitation and progressive conduction system disease, 2, 5, 8, 20 cardiac electrophysiology was studied in transgenic mice. Surface ECGs ( Figure 4A ) showed that Ϸ50% of TG N488I mice had shortened PR intervals, indicative of a reduction in the physiological time delay between atrial and ventricular electrical activation, and delta waves, suggestive wt (E), and TG N488I (F) hearts stained with hematoxylin and eosin. Note markedly distended myocytes with vacuolated cytoplasm (arrow) in TG N488I samples (magnification 400ϫ). PAS-stained sections from wild-type (G), TG wt (H), and TG N488I (I) hearts (400ϫ). Sections stained with PAS followed by diastase digestion were negative (data not shown). J, TG N488I heart section stained with toluidine blue revealed markedly distended myocytes filled with glycogen (homogeneous purple pools). Inset shows granular appearance of organelles and cytoplasm from a wild-type heart. K, Electron micrograph of a hypertrophied TG N488I myocyte shows abundant non-membranebound glycogen (pale, fine-grained material), displaced mitochondria (arrowhead), and peripheral myofibrils (uranyl acetate and lead citrate; barϭ3 m).
of ventricular preexcitation. Concurrent ECGs and 2D echocardiography indicated that preexcitation was associated with asynchronous left ventricular contraction. Preexcitation was not found in any TG wt mice (nϭ18) or in Ͼ200 wild-type mice.
Invasive electrophysiological studies ( Figure 4B ) confirmed preexcitation in 2 independent TG N488I lines. Two distinct pathways for atrioventricular conduction were observed with different coupling intervals and different ventricular morphologies of excitation (our unpublished results). Continuous ECG recordings showed that multiple patterns of ventricular activation coexisted in the same animal ( Figure   4C ), analogous to electrophysiological observations in human patients with PRKAG2 mutations and WPW. 8 TG N488I mice had a lower basal heart rate ( Table) , and on continuous ECG monitoring (nϭ6), all exhibited deterioration of the conduction system with frequent spontaneous episodes of sinus bradycardia (Ͻ300 bpm) and various escape rhythms, including paroxysmal supraventricular tachycardia and atrial fibrillation ( Figure 4D ). Stress (induction of anesthesia and/or manipulation) resulted in syncope and led to sudden death in 5 TG N488I mice; ECG monitoring of stressed TG N488I mice suggested severe and persistent sinus bradycardia as the cause of death. Spontaneous mortality, associated with severe left ventricular dysfunction, was observed in TG N488I mice 20 to 40 weeks old ( Figure 5A ). Continuous ECG recording in 3 old mice (Ͼ30 weeks old) ( Figure 5B) demonstrated severe sinus bradycardia but not tachyarrhythmia or atrioventricular block before death.
To examine the specialized cells of the conduction system, TG N488I mice were crossed with minK-LacZ mice, 17 which transcribe ␤-galactosidase mRNA under control of the minK promoter so that ␤-galactosidase was expressed in cardiac conduction system cells. Compound mutant mice (MinK/ TG N488I ) had no evidence of gross abnormalities in the cardiac conduction system compared with wild-type MinK mice (data not shown). Although the gross organization of the conduction system was normal, serial histological examination of the atrioventricular junction in TG N488I mice showed important differences ( Figure 6 ). The annulus fibrosis, which normally insulates the atria from the ventricles, was a continuous structure in both wild-type and TG wt hearts. However, in hypertrophied TG N488I hearts, the annulus fibrosis was thinned, stretched, and disrupted, most notably at the atrioventricular junction above the interventricular septum. This region contained many vacuolated, glycogen-loaded Early mortality and preterminal heart rhythm observed in TG N488I mice. A, Kaplan-Meyer survival curves of (diamonds) TG N488I and (circles) TG wt mice. B, Holter monitor tracing from a 44-week-old TG N488I mouse, taken shortly before death, shows a severe bradycardia (heart rate of this TG N488I mouse was Ͻ60 bpm, whereas normal mouse heart rate is Ͼ400 bpm). Note that PR interval remains short (normal Ϸ30 ms). Inset shows a magnified P-QRS complex (barϭ20 ms).
myocytes. However, all TG N488I hearts studied (nϭ5) showed loss of fibrous separation between atrial and ventricular myocardium in the anterior septum lateral to the aortic outflow tract and adjacent to the tricuspid annulus (the region defined by surface ECG criteria as the locus of preexcitation). Furthermore, 2 TG N488I hearts also showed disruption of annulus fibrosis in the posterior septal region, consistent with multiple accessory AV connections, as suggested by continuous ECG monitoring ( Figure 4C ). No distinct bypass tracts were observed.
AMPK activity, with and without AMP stimulation, was measured in cardiac extracts from young TG wt and TG N488I mice after immunoprecipitation with ␣-subunit-specific antibodies ( Figure 7) . AMP stimulation produced a modest (Ͻ2-fold) increase in ␣ 1 or ␣ 2 subunit-associated AMPK activity in wild-type or transgenic heart extracts. Both ␣ 1 and ␣ 2 subunit-associated basal AMPK activity was increased in TG N488I mice compared with TG wt mice. In TG N488I hearts, AMPK activity associated with the ␣ 2 subunit demonstrated a much more dramatic increase (Ϸ8-fold versus Ͻ2-fold) than the increase in ␣ 1 subunit-associated AMPK activity in these same mice (Figure 7 ).
Discussion
We demonstrate that transgenic mice overexpressing mutant PRKAG2 exhibit the cardiomyopathy and electrophysiological abnormalities found in humans with this mutation. [2] [3] [4] [5] Transgenic mice expressing mutant PRKAG2 demonstrated increased cardiac enzyme activity and cardiac glycogen storage. In contrast, overexpression of wild-type PRKAG2 produced only mild glycogen accumulation, mild cardiac hypertrophy, and no conduction system disease. These data establish PRKAG2 mutations as a glycogen storage cardiomyopathy and confirm for the first time the direct relationship between PRKAG2 mutations, AMPK activation, glycogen storage, and the features of human disease. Analyses of the atrioventricular junction of these mice explain the preexcitation found in mice and presumably humans with these mutations.
Increased cardiac expression of either wild-type or mutant PRKAG2 cDNA led to increased glycogen storage. Pharmacological activation of AMPK has previously been shown to increase glycogen. 21, 22 Intermediate glycogen levels observed in TG wt mice were presumably a result of a small, undetectable increase in AMPK activity (Figure 7) . 6, 23 By age 5 weeks, TG N488I hearts contained Ϸ5-fold more glycogen than TG wt hearts and 30-fold more glycogen than nontransgenic wild-type hearts, consistent with the significant increases in AMPK activity detected in the transgenic animals ( Figure 7) .
Comparison of the pathophysiology of PRKAG2 mutations with other glycogen storage diseases provides useful clues to the mechanism of cardiomyopathy and conduction system disease. Cardiac hypertrophy is a common feature of several other inherited disorders of glycogen metabolism. 24 -26 Mice lacking the ␣-glucosidase gene, a model of Pompe's disease, show progressive accumulation of glycogen (up to 140 g/mg protein) and cardiac hypertrophy, 12, 27 quite like TG N488I mice, thereby supporting the concept that glycogen accumulation per se accounts for cardiac hypertrophy.
Many glycogen storage disorders also cause conduction system disease, and some have ECG patterns suggestive of preexcitation. Although an ECG pattern of WPW is sometimes found in Pompe disease, 15, 25 it is more frequently observed with Danon disease, a cardiac and skeletal myop- wt , and TG N488I mice (nϭ3 to 4 per group). AMPK activity was measured after immunoprecipitation with antibodies specific for ␣ 1 or ␣ 2 . TG N488I extracts had significantly more basal ␣ 1 -subunit-associated AMPK and ␣ 2 -subunit associated AMPK activity than TG wt or wild-type hearts (*PϽ0.02, #PϽ0.002).
athy with encephalopathy, preexcitation, and bradyarrhythmias. 26 Because no histologically defined bypass tracts have been identified, these individuals are often presumed to have accelerated AV nodal conduction or abnormal fasciculoventricular connections. 15, 16, 20 Disruption of annulus fibrosis has also been identified in some patients with WPW 28,29 unassociated with glycogen storage disease. We suggest that disruption of the annulus fibrosis by glycogen-filled myocytes, rather than distinct bypass tracts, is the likely mechanism for preexcitation in these diseases. Distinguishing between WPW caused by muscular bypass tracts rather than disruption of the annulus fibrosis may have clinical significance, particularly with regard to ablation therapies.
Our studies also suggest an explanation for the cardiac conduction defects caused by glycogen accumulation. 2, 5, 15, 24, 26 Glycogen accumulation after conduction system development is complete leads to remodeling of atrioventricular conduction pathways in TG N488I mice. Whether glycogen accumulation in humans bearing these mutations occurs during or after conduction system development is unclear. Perhaps postnatal reversal of glycogen accumulation will restore normal cardiac conduction. Analyses of transgenic mice bearing mutant PRKAG2 whose expression can be controlled will answer this question.
